Bristol-Myers blockbuster Opdivo fails to meet goal of brain tumour study Medical Dialogues Bureau8 Sept 2019 9:15 AM ISTThe drug, Opdivo, when used along with the current standard of care for glioblastoma multiforme, did not prevent cancer from spreading when compared...
Bayer disagrees with German Government decision to ban Glyphosate from end of 2023 Medical Dialogues Bureau6 Sept 2019 9:00 AM IST"Such a ban would ignore the overwhelming scientific assessments of competent authorities around the world that have determined for more than 40 years...
Novartis sees gene, cell therapy reaching up to 15pc of total revenue in midterm Medical Dialogues Bureau5 Sept 2019 9:15 AM ISTZURICH: Novartis sees cell and gene therapies accounting for up to 15% of its total revenue in the midterm from a much lower level at present, a Swiss...
Delhi HC given Green Signal to Natco Pharma for generic of Novartis cancer drug Ceritinib Farhat Nasim1 Sept 2019 2:33 PM ISTNew Delhi: In a major relief to Natco, the Delhi High Court has lifted a ban on Natco Pharma from manufacturing fresh stock of on-small cell lung...
Mylan gets tentative USFDA nod for generic of Eli Lilly lung cancer drug Alimta Medical Dialogues Bureau31 Aug 2019 9:30 AM ISTAlimta is Lilly's third biggest-selling drug. The Indianapolis-based drugmaker reported second-quarter sales of $577.8 million for the medicine.U.S:...
Roche personalized cancer treatment Rozlytrek priced at Rs 12 lakh per month Medical Dialogues Bureau17 Aug 2019 9:15 AM ISTRozlytrek was approved by the U.S. Food and Drug Administration on Thursday to treat certain types of solid tumours, which show rare genetic anomalies...
Natco Pharma to focus to scale up Cancer treatment biz in China: MD VC Nannapaneni Medical Dialogues Bureau12 Aug 2019 12:26 PM ISTNew Delhi: Natco Pharma is focusing on filing of cancer treatment drugs in China, the world's second largest pharmaceutical market, as part of its...
Novartis, Gilead costly cancer therapies Yescarta, Kymriah losing patients to experimental treatments Medical Dialogues Bureau3 Aug 2019 9:15 AM ISTBoth Gilead's Yescarta and Novartis's Kymriah - which are part of a class of therapies known in the medical field as "CAR-T" - were approved in 2017....
Bristol-Myers posts strong second quarter as Eliquis, Orencia sales propel Medical Dialogues Bureau28 July 2019 9:17 AM ISTSales of Eliquis, which Bristol-Myers shares with Pfizer Inc (PFE.N), rose 24% to $2.04 billion, while Orencia sales rose 9% to $778 million, both...
Allergan announces worldwide recall of textured breast implant tied to rare cancer Medical Dialogues Bureau26 July 2019 9:15 AM ISTThe U.S. Food and Drug Administration said it called for the removal after new information showed Allergan Inc's Biocell breast implants account for a...
Pfizer gets USFDA nod for biosimilar to Rituximab Medical Dialogues Bureau25 July 2019 8:59 AM ISTRuxience is a mAb biosimilar to Rituxan which works by targeting a protein called CD20, which is present on the surface of B cells. Ruxience is...
Cancer Drug Patent Issues: Delhi HC junks Bayer plea to block Natco Pharma Regonat Farhat Nasim15 July 2019 2:52 PM ISTNew Delhi: The Delhi High Court recently junked the injunction petition filed by the German Drugmaker to restrain the Hyderabad-based Natco Pharma...
